Halley Gilbert

Ms. Gilbert is currently the Chief Legal Officer of NeoGenomics, Inc., a premier cancer diagnostic, pharma services and informatics company. She brings to the role over 20 years of biotechnology industry management and operations expertise. Most recently, Ms. Gilbert served as Chief Operating Officer of Adagio Therapeutics, Inc., a company focused on developing broadly neutralizing antibodies for the prevention and treatment of COVID-19 and future coronavirus outbreaks. In just over one year as an operating company, her contributions supported the seamless transition of Adagio to public company status, significant financings, advancing the pipeline and building the team. Previously, Ms. Gilbert spent 12 years in various roles of increasing scope and responsibility at Ironwood Pharmaceuticals, Inc., including Senior Vice President of Corporate Development and Chief Administrative Officer with oversight of corporate and business development, legal, compliance and government affairs. Additionally, Ms. Gilbert served as Ironwood’s Senior Vice President, Chief Legal Officer and Corporate Secretary. Prior to joining Ironwood, she was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. Ms. Gilbert also served as a corporate counsel at Genzyme Corp., prior to its acquisition by Sanofi. She began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the boards of directors of Arcutis Biotherapeutics, Inc., CytomX Therapeutics, Inc. and Vaxcyte, Inc. Previous board roles included Dermira, Inc., prior to its acquisition by Eli Lilly and Company, and Achaogen, Inc. Ms. Gilbert holds a BA from Tufts University and a JD from Northwestern University School of Law.